Comparative Benchmarking
In the context of the broader market, TOVX competes directly with industry leaders such as DRMA and RDHL. With a market capitalization of $7.85M, it holds a leading position in the sector. When comparing efficiency, TOVX's gross margin of N/A stands against DRMA's N/A and RDHL's 60.60%. Such benchmarking helps identify whether Theriva Biologics Inc is trading at a premium or discount relative to its financial performance.
